Fredun Pharmaceuticals Ltd Share Price

Pharmaceuticals - Indian - FormulationsNSE
₹1,693.90
-14.10-0.83% (1D)
As on 20 Nov 2026 at 15:59
As of 20 Nov 2026 at 15:59, Fredun Pharmaceuticals Ltd is trading at ₹1,693.90. The 52-week range stands at ₹453.59–₹1,735.00, with a market cap of ₹2.90 thousand crore. At a P/E of 54.17 and a dividend yield of 0.01%, it is a small-cap stock in the Pharmaceuticals sector.

FREDUN Price Chart

Market Cap
₹2.90K Cr
PE Ratio
54.17
ROCE
20.50%

Fredun Pharmaceuticals Ltd Performance

Fredun Pharmaceuticals Ltd Fundamentals

Know More
Market Cap₹2.90K Cr
ROE16.16%
P/E Ratio (TTM)54.17
EPS (TTM)₹31.26
P/B Ratio8.06
Dividend Yield0.01%
Industry P/E91.72
Book Value₹209.98
Debt to Equity0.74
Face Value₹10

Fredun Pharmaceuticals Ltd Shareholding Pattern

Know More
Promoter43.6%
Foreign Institutions0.7%
Mutual Funds0%
Domestic Institutions1.3%
Public54.4%

Fredun Pharmaceuticals Ltd Financial Statements

Know More
No data for this view.

Fredun Pharmaceuticals Ltd Peer Comparison

Know More
StocksLTP(₹)Market Cap(Cr)52 Week Low-High(₹)
Sun Pharmaceutical Industries Ltd
₹1,885.10
-14.90(-0.78%)
4,52,298.61,583.7 - 2,046.9
Torrent Pharmaceuticals Ltd
₹4,698.80
87.80(+1.90%)
1,78,727.33,672.3 - 5,250.0
Dr Reddys Laboratories Ltd
₹1,390.50
-10.40(-0.74%)
1,16,144.51,101.0 - 1,414.9
Cipla Ltd
₹1,414.95
-3.55(-0.25%)
1,14,312.11,165.7 - 1,539.7
Lupin Ltd
₹2,010.00
11.20(+0.56%)
91,915.91,892.9 - 2,529.5

About Fredun Pharmaceuticals

Incorporated in 1987 as a Private Limited company, Fredun Pharmaceuticals Limited (FPL) was converted into a Public limited company in Mar.'94. The Company was promoted by Nariman Medhora and Daulat N Medhora. The promoters initially established D N Pharma, a proprietary firm, for the manufacture and export of pharmaceutical formulations. Since 1993, D N Pharma's operations were phased out in order to switch over the business to FPL. The Company is well diversified in the business ranging from Formulations to Diagnostics to Consultancy. The Company has an unique range of products, from niche formulations , anti-diabetics to the latest antiretroviral and anti - Hypertensive products. It supplies finished formulations to over 42 Countries globally. It is associated with many Governments of different countries which have also realised the need for robust and consistent healthcare systems. The Company was set up with the objective of providing facilities for manufacturing and marketing of various pharmaceutical formulations like tablets, capsules, dry-syrups and ointments. It then set up a formulation unit at Palghar (Thane District), Maharashtra, which commenced commercial production in Aug.'94. FPL had been carrying out manufacturing operations on loan licence for reputed pharmaceutical companies like Cipla. It also manufactured for some merchant exporters, including Merind. In Apr.'96, the company came out with a public issue to register its products in the overseas market for exports; to part-finance the expansion of its business activities and to repay one of the term loans and unsecured loans to reduce the interest burden. Company is very much optimistic of revival of company's turnover by having excellent export order in hand. Company also in process of registering various drugs with different countires such as Nepal, Tanzaniya, Uganda & Sri Lanka. In 2013, Company launched 36 new products and filed 60 new products for registration. It launched a herbal dietary supplement in Africa. During 2015, three new granulation departments were introduced to the existing two departments. It launched 19 new products under the Cosmeceuticals OEM Division in 2023. It introduced 14 new products in the pet pharmaceuticals line, with another 36 in the works. It launched 16 products into the Pet Treat and Nutritional Supplement category. In FY 2024, Company launched over 110 products under the Fredun Gx brand in India, including Anti-Diabetics, Anti-Hypertensives, Anti-biotics & Anti-fungal. During FY 2025 a second Italian Tube Filling Machine and two Automatic Carton Packaging Machines have been installed. Company acquired One Pet Stop Pvt Ltd, adding grooming services and access to over 4,000 pet owners. Fredun launched Freossi Tone+ (for lactation and milk quality) and Freossi Power (for joint health and mobility), targeting livestock like cows, buffaloes, horses, and cattle in 2025 Fredun Retail Pvt Ltd. was incorporated as subsidiary of the Company effective on February 4, 2025. Company has developed and launched many new molecules like antihypertensive, antidiabetic, ARVs and even narcotics in FY26.

Parent Organisation—
Founded1987
Managing DirectorFredun N Medhora
NSE SymbolFREDUN

Fredun Pharmaceuticals Ltd Resistance and Support levels

R31,770.53R21,736.57R11,715.59S11,647.67S21,626.69S31,592.731,693.90

Fredun Pharmaceuticals Ltd Technicals

Current Price
₹1,693.90 ₹14.10 (-0.83%)
Bearish
0
Bullish
12
  • 20 Day11.7%
  • 50 Day15.3%
  • 100 Day17.3%
  • 200 Day17.3%

Fredun Pharmaceuticals Ltd Latest News

View More
14 NOV 2026 | Saturday
Fredun Pharmaceuticals' board reviewed a monitoring report for the quarter ended September 30, 2026
14 NOV 2026 | Saturday
Fredun Pharmaceuticals confirms Rs 128.78 crore preferential issue use, despite reporting observations
05 OCT 2026 | Monday
Fredun Pharmaceuticals allots shares to warrant holders following board meeting on October 3, 2026
04 OCT 2026 | Sunday
Fredun Pharmaceuticals allotted shares to warrant holders following conversion and shareholder approval
03 OCT 2026 | Saturday
Fredun Pharmaceuticals allotted shares to warrant holders following conversion and shareholder approval
28 SEPT 2026 | Monday
Fredun Pharmaceuticals halts trading for insiders pending financial results announcement
22 SEPT 2026 | Tuesday
Fredun Pharmaceuticals converts warrants, allotting shares to warrant holders and investors
17 SEPT 2026 | Thursday
Fredun Pharmaceuticals allots shares to warrant holders including Alchemy Capital and Ajay Aggarwal
16 SEPT 2026 | Wednesday
Fredun Pharmaceuticals allots shares to warrant holders including Alchemy Capital and Ajay Aggarwal
15 AUG 2026 | Saturday
Fredun Pharmaceuticals confirms Rs 111.53 crore preferential issue use, per Care Ratings

2026

Board MeetingAnnounced
Quarterly ResultRelease dateCheck Latest financial
Board MeetingAnnounced
Board MeetingAnnounced
Board MeetingAnnounced
Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Board MeetingAnnounced

Frequently asked questions

The share price of Fredun Pharmaceuticals Ltd is ₹1,693.90 as of 20 Nov 2026 at 15:59.

Not sure where to start?

Book a free 30-minute consultation with our investment experts today!

Invest Now